Evidence map›Paper›PMID 40681188›Full record

ArticleBMJ open2025

Preoperative partial breast reirradiation and repeat breast-conserving surgery in patients with recurrent breast cancer: the prospective single-arm REPEAT trial - a study protocol.

Yasmin Civil, Lisca Wurfbain, Lysanne Jonker, Maurice van der Sangen, Arlene Oei, Katya Duvivier, Nina Bijker, Philip Meijnen, Zdenko van Kesteren, Miguel Palacios and 8 more

Abstract readClinical Trial Protocol
In one paragraph

Article in BMJ open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Yasmin Civil *Department of Radiation Oncology, Amsterdam UMC Location VUmc, Amsterdam, Noord-Holland, The Netherlands y.civil@amsterdamumc.nl.ORCID http://orcid.org/0000-0001-5890-2451
Lisca Wurfbain *Department of Radiation Oncology, Amsterdam UMC Location VUmc, Amsterdam, Noord-Holland, The Netherlands.
Lysanne JonkerDepartment of Radiation Oncology, Amsterdam UMC Location VUmc, Amsterdam, Noord-Holland, The Netherlands.
Maurice van der SangenDepartment of Radiation Oncology, Catharina Hospital, Eindhoven, Noord-Brabant, The Netherlands.
Arlene OeiDepartment of Radiation Oncology, Amsterdam UMC Location VUmc, Amsterdam, Noord-Holland, The Netherlands.
Katya DuvivierCancer Treatment and Quality of Life, Cancer Center Amsterdam, Amsterdam, The Netherlands.
Nina BijkerDepartment of Radiation Oncology, Amsterdam UMC Location VUmc, Amsterdam, Noord-Holland, The Netherlands.
Philip MeijnenDepartment of Radiation Oncology, Amsterdam UMC Location VUmc, Amsterdam, Noord-Holland, The Netherlands.
Zdenko van KesterenDepartment of Radiation Oncology, Amsterdam UMC Location VUmc, Amsterdam, Noord-Holland, The Netherlands.
Miguel PalaciosDepartment of Radiation Oncology, Amsterdam UMC Location VUmc, Amsterdam, Noord-Holland, The Netherlands.
Ellis BarbéCancer Treatment and Quality of Life, Cancer Center Amsterdam, Amsterdam, The Netherlands.
Willemien Menke-van der Houven van OordtCancer Treatment and Quality of Life, Cancer Center Amsterdam, Amsterdam, The Netherlands.
Gwen DiepenhorstDepartment of Surgery, Amsterdam UMC Location VUmc, Amsterdam, Noord-Holland, The Netherlands.
Victor ThijssenDepartment of Radiation Oncology, Amsterdam UMC Location VUmc, Amsterdam, Noord-Holland, The Netherlands.
Berend SlotmanDepartment of Radiation Oncology, Amsterdam UMC Location VUmc, Amsterdam, Noord-Holland, The Netherlands.
Joost VerhoeffDepartment of Radiation Oncology, Amsterdam UMC Location VUmc, Amsterdam, Noord-Holland, The Netherlands.
Robert-Jan SchipperDepartment of Surgery, Catharina Hospital, Eindhoven, Noord-Brabant, The Netherlands.
Desirée van den BongardDepartment of Radiation Oncology, Amsterdam UMC Location VUmc, Amsterdam, Noord-Holland, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionOver the past decades, interest in second breast-conserving therapy (BCT) has increased due to, among others, advances in radiotherapy techniques. Preoperative partial breast irradiation (PBI) is an experimental treatment for patients with low-risk primary breast cancer. This approach can downstage the tumour and may possibly reduce toxicity and improve cosmetic outcomes compared with postoperative radiotherapy. This study aims to evaluate the feasibility of single-dose preoperative PBI and second breast-conserving surgery (BCS) for patients with an ipsilateral recurrent breast event (IRBE) after previous BCT. METHODS AND ANALYSIS: The REPEAT trial is a multicentre, prospective, single-arm trial investigating ablative single-dose preoperative PBI in patients with an IRBE. Eligible patients are ≥50 years, have a unifocal non-lobular invasive breast cancer ≤2 cm, Bloom-Richardson grade 1 or 2, oestrogen receptor-positive, human epidermal growth factor receptor 2-negative and clinically negative axillary lymph nodes. The study plans to enrol 25 patients. Radiotherapy planning will involve the use of CT and MRI in the treatment position. Single-dose PBI of 20 Gy to the tumour and 15 Gy to the surrounding 2 cm of breast tissue will be delivered using a conventional or MR-guided linear accelerator. Tumour response will be monitored preoperatively using MRI and liquid biopsies to identify biomarkers for evaluating radiosensitivity. BCS will be performed 3 (±one) weeks post PBI. The primary endpoint is the incidence of grade 2 or higher treatment-associated acute toxicity within 90 days. Secondary endpoints include the evaluation of acute (grade 1) and late toxicity, radiologic and pathologic response, mastectomy rate, patient-reported outcomes, cosmetic outcome, local, regional and distant recurrence rates, survival outcome and biomarkers in liquid biopsies and tumour tissue. Patients will be followed up to 5 years after PBI. ETHICS AND DISSEMINATION: Ethical approval from the Medical Research Ethics Committee of the Amsterdam UMC has been obtained (NL85983.018.24). The results will be disseminated via peer-reviewed academic journal and presentation at conferences. In addition, summaries will be shared with the participating patients. TRIAL REGISTRATION NUMBER: The trial was registered prospectively on October 11

Indexed as

Breast NeoplasmsMastectomy, SegmentalNeoplasm Recurrence, LocalRe-IrradiationClinical Trials, Phase II as TopicFemaleHumansMiddle AgedMulticenter Studies as TopicPreoperative CareProspective StudiesBreast tumoursQuality of LifeRadiation oncologyRADIOTHERAPYToxicity

Identifiers

PMID40681188
PMCPMC12273098

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.